EBV and HHV-6
Cross-source consensus on EBV and HHV-6 from 1 sources and 5 claims.
1 sources · 5 claims
How it works
Risks & contraindications
Evidence quality
Highlighted claims
- EBV reactivation by SARS-CoV-2 triggers expression of antigens that cross-react with human tissue, driving autoimmunity. — Long COVID, ASIA Syndrome, and Autoimmunity: Insights from the 14th International Congress
- HHV-6 reactivation is strongly linked to neuroinflammatory and neuro-autoimmune disorders including Alzheimer's disease, Parkinson's disease, ME/CFS, lupus, and multiple sclerosis. — Long COVID, ASIA Syndrome, and Autoimmunity: Insights from the 14th International Congress
- Viral dUTPases released by EBV and HHV-6 activate NF-κB, impair T-cell function, and cross the blood-brain barrier, directly producing neuroinflammation. — Long COVID, ASIA Syndrome, and Autoimmunity: Insights from the 14th International Congress
- IgG, IgM, and IgA antibodies against EBV and HHV-6 dUTPases were elevated in Long COVID patients but not in healthy controls. — Long COVID, ASIA Syndrome, and Autoimmunity: Insights from the 14th International Congress
- SARS-CoV-2 peptides cross-react with heat shock proteins HSP60 and HSP90, and anti-HSP autoantibodies are associated with endothelial damage and cardiovascular disorders. — Long COVID, ASIA Syndrome, and Autoimmunity: Insights from the 14th International Congress